Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Goldsite Diagnostics
Shenzhen, Guangdong, China
- Ownership
- Private
- Employees
- ~283
- Development stage
- Other
01
Overview
Goldsite Diagnostics’ products—including the Specific Protein Analyzer, GPP-100 nephelometer, and Nephstar—are commercially available in over 60 countries and are ISO 9001 and ISO 13485 certified, with GMP-standard manufacturing. Their assays cover more than 50 diagnostic targets for diseases including diabetes, cardiac, inflammation, immune, and hormonal markers.
- Therapeutic areas
- CardiovascularImmunologyEndocrinologyRheumatology
- Modalities
- DeviceReagentsClinical instrument (including nephelometry, protein analyzers, immunoassay)
- Industry
- Protein Biomarker Diagnostics
02
Partnerships
BIOCOM Africa (distribution in Africa)SPICA Medtech Corp (US regulatory/agent)
Beyond the preview
Go deeper on Goldsite Diagnostics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Goldsite Diagnostics.